Cogent Biosciences (NASDAQ:COGT) Price Target Cut to $19.00 by Analysts at JPMorgan Chase & Co.

Cogent Biosciences (NASDAQ:COGT) had its price objective decreased by research analysts at JPMorgan Chase & Co. from $22.00 to $19.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the technology company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 113.48% from the stock’s previous close.

COGT has been the topic of a number of other research reports. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Cogent Biosciences in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $19.00 price target on shares of Cogent Biosciences in a report on Monday, June 17th. Finally, Wedbush reiterated a “neutral” rating and set a $10.00 price target on shares of Cogent Biosciences in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cogent Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Cogent Biosciences Price Performance

COGT stock traded up $0.01 during mid-day trading on Wednesday, hitting $8.90. 13,236 shares of the stock were exchanged, compared to its average volume of 1,590,243. The stock has a market capitalization of $850.93 million, a price-to-earnings ratio of -3.58 and a beta of 1.71. The business has a fifty day moving average price of $8.82 and a 200 day moving average price of $7.50. Cogent Biosciences has a 12 month low of $3.67 and a 12 month high of $13.23.

Cogent Biosciences (NASDAQ:COGT) last issued its earnings results on Tuesday, August 6th. The technology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period last year, the firm earned ($0.59) earnings per share. As a group, equities analysts forecast that Cogent Biosciences will post -2.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Cogent Biosciences

Several hedge funds have recently bought and sold shares of the business. Kynam Capital Management LP increased its holdings in shares of Cogent Biosciences by 45.2% during the first quarter. Kynam Capital Management LP now owns 8,500,000 shares of the technology company’s stock valued at $57,120,000 after acquiring an additional 2,645,234 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Cogent Biosciences by 27.1% during the first quarter. Vanguard Group Inc. now owns 5,765,705 shares of the technology company’s stock valued at $38,746,000 after buying an additional 1,231,050 shares during the last quarter. Redmile Group LLC increased its position in shares of Cogent Biosciences by 36.0% during the first quarter. Redmile Group LLC now owns 3,962,602 shares of the technology company’s stock valued at $26,629,000 after acquiring an additional 1,048,580 shares in the last quarter. Eventide Asset Management LLC raised its holdings in Cogent Biosciences by 3.9% in the 4th quarter. Eventide Asset Management LLC now owns 2,232,968 shares of the technology company’s stock worth $13,130,000 after acquiring an additional 82,968 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in Cogent Biosciences by 12,785.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,099,357 shares of the technology company’s stock valued at $14,097,000 after acquiring an additional 2,083,065 shares in the last quarter.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.